Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders

References

• Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10(2):R45–8.
   PubMed Web of Science ®Google Scholar
• Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;17:212.
   PubMed Web of Science ®Google Scholar
• Harigai M, Nanki T, Koike R, Tanaka M, Watanabe-Imai K, Komano Y, et al. Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: a nationwide cohort study in Japan. Mod Rheumatol. 2016;26(5):642–50.
   PubMed Web of Science ®Google Scholar
• Yamada T, Nakajima A, Inoue E, Tanaka E, Taniguchi A, Momohara S, et al. Incidence of malignancy in Japanese patients with rheumatoid arthritis. Rheumatol Int. 2011;31(11):1487–92.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Radner H, Mjaavatten MD, Greenberg JD, Kavanaugh A, Kishimoto M, et al. Incidence and predictors of biological antirheumatic drug discontinuation attempts among patients with rheumatoid arthritis in remission: a CORRONA and NinJa collaborative cohort study. J Rheumatol. 2015;42:2238–2246.
   PubMed Web of Science ®Google Scholar
• Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54(3):692–701.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Immunodeficiency-Associated Lymphoproliferative Disorders. 4th ed. Lyon: IARC Publications; 2017; p. 443–464.
   Google Scholar
• Ellman MH, Hurwitz H, Thomas C, Kozloff M. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly. J Rheumatol. 1991;18(11):1741–3.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Maier AL, Fraser PA, Coblyn JS. Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J Rheumatol. 1998;25(2):238–42.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 2007;56(5):1433–9.
   PubMed Web of Science ®Google Scholar
• Kamel OW, van de Rijn M, Weiss LM, Zoppo GJ, Del Hench PK, Robbins BA, et al. Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med. 1993;328(18):1317–21.
   PubMed Web of Science ®Google Scholar
• Salloum E, Cooper DL, Howe G, Lacy J, Tallini G, Crouch J, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. JCO. 1996;14(6):1943–9.
   PubMed Web of Science ®Google Scholar
• Tokuhira M, Watanabe R, Nemoto T, Sagawa M, Tomikawa T, Tamaru J, et al. Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis. Leukemia and Lymphoma. 2012;53:616–23.
   PubMed Web of Science ®Google Scholar
• Ichikawa A, Arakawa F, Kiyasu J, Sato K, Miyoshi H, Niino D, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013;91(1):20–8.
   PubMed Web of Science ®Google Scholar
• Saito S, Kaneko Y, Yamaoka K, Tokuhira M, Takeuchi T. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate. Rheumatol (United Kingdom). 2017;56:940–6.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Medsger TA, Pinals RS, Bloch DA, Edworthy SM, Hunder GG, et al. The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.
   PubMed Web of Science ®Google Scholar
• Steinbrocker O, Traeger GH, Battermann RC. Therapeutic criteria in rheumatoid arthritis. JAMA. 1949;140(8):659–62.
   PubMed Web of Science ®Google Scholar
• Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. JCO. 1989;7(11):1630–6.
   PubMed Web of Science ®Google Scholar
• The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A Predictive Model for Aggressive Non-Hodgkin’s Lymphoma. N Engl J Med. 1993;329:987–94.
   PubMed Web of Science ®Google Scholar
• Yamada K, Oshiro Y, Okamura S, Fujisaki T, Kondo S, Nakayama Y, et al. Clinicopathological characteristics and rituximab addition to cytotoxic therapies in patients with rheumatoid arthritis and methotrexate-associated large B lymphoproliferative disorders. Histopathology 2015;67(1):70–80.
   PubMed Web of Science ®Google Scholar
• Tokuhira M, Saito S, Okuyama A, Suzuki K, Higashi M, Momose S, et al. Clinicopathologic investigation of methotrexate-induced lymphoproliferative disorders, with a focus on regression. Leuk Lymphoma 2018;59:1143–1152.
   PubMed Web of Science ®Google Scholar
• Hoshida Y, Xu J-X, Fujita S, Nakamichi I, Ikeda J, Tomita Y, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol. 2007;34(2):322–31.
   PubMed Web of Science ®Google Scholar
• Harigai M. Lymphoproliferative disorders in patients with rheumatoid arthritis in the era of widespread use of methotrexate: a review of the literature and current perspective. Mod Rheumatol. 2018;28(1):1–8.
   PubMed Web of Science ®Google Scholar
• Tokuhira M, Tamaru J, Kizaki M. Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders. JCEH. 2019;59(2):72–92.
   Google Scholar
• Balandraud N, Texier G, Massy E, Muis-Pistor O, Martin M, Auger I, et al. Long term treatment with abatacept or tocilizumab does not increase Epstein-Barr virus load in patients with Rheumatoid arthritis – a three years retrospective study. PLoS One. 2017;12(2):e0171623–13.
   PubMed Web of Science ®Google Scholar
• Katsuyama T, Sada KE, Yan M, Zeggar S, Hiramatsu S, Miyawaki Y, et al. Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents. Mod Rheumatol. 2017;26:642–50.
   Google Scholar